MEDIPOST announced that ‘PNEUMOSTEM^®’, a preventive treatment of bronchial pulmonary dysplasia of premature babies has been selected as a ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency under Ministry of Health and Welfare.

National evidence based healthcare collaborating agency evaluated ‘PNEUMOSTEM^®’ of MEDIPOST as a treatment alternative of bronchial pulmonary dysplasia where no treatment exists, “showing lowering effects on disease progression and complications and easy application and low risks” in its analysis report.

Also, it added that “’PNEUMOSTEM^®’ has been selected as an orphan drug in Europe and US and it is expected it would be usefully applied in both prevention and treatment of bronchial pulmonary dysplasia in medical market in Korea within 2 years”.